Abiopharma

We are still in the early stages of our first commercial launch, but are encouraged by the initial clinical interest in our first-in-class FcRn blocker and the feedback we are hearing from patients and their supporters, said Tim Van Hauwermeiren, Chief Executive Officer of argenx.